TC BioPharm's ADS Ratio Change Explained
TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company innovating in gamma-delta T cell therapies, has made a noteworthy announcement regarding its ratio of American Depositary Shares (ADSs) to ordinary shares. This change entails a shift from one ADS representing two hundred ordinary shares to one ADS representing four thousand ordinary shares. Such modifications enable better alignment for investors and potentially enhance the trading dynamics of the company's securities.
Understanding the Impact of the ADS Ratio Change
The Company’s decision to implement the ADS ratio change is expected to function similarly to a reverse ADS split of 1-for-20. Under this new format, current holders of ADSs will need to exchange twenty of their ADSs for a single new ADS. This process allows for a more efficient trading framework while maintaining the overall number of ordinary shares unchanged, thus preserving shareholder equity without diluting current holdings.
Trading Adjustments and Investor Guidance
Upon the effective date of this change, holders can rest assured that trading will continue under the symbol 'TCBP' on the Nasdaq Capital Market. The Bank of New York Mellon will facilitate the exchange process and ensure seamless transitions for the investors involved. Notably, there will be no issuance of fractional new ADSs; instead, any fractional interests will be aggregated and sold, with proceeds distributed to ADS holders, ensuring that all investments are managed equitably.
Potential Effects on Share Price
Following the ADS ratio change, it is anticipated that the trading price of the ADS will experience an increase proportionate to the ratio adjustment. However, TC BioPharm has noted that there is no guarantee that the price post-ratio change will be equivalent to or higher than the previous trading price.
About TC BioPharm
TC BioPharm has emerged as a pioneering force in the biopharmaceutical sector, concentrating on gamma-delta T cell therapies for cancer treatments. The company is dedicated to advancing its proprietary technology, particularly with a focus on the treatment of acute myeloid leukemia. With a robust pipeline and an emphasis on rigorous clinical studies, TC BioPharm is committed to delivering breakthrough therapies that can change the landscape of cancer treatment.
Leading the Way in T Cell Therapy Development
As a leader in developing gamma-delta T cell therapies, TC BioPharm stands out by being the first company to engage in phase II clinical trials specifically for oncology applications. The organization's ongoing efforts include investigator-initiated clinical trials to explore the potential of its unmodified gamma-delta T cell product line. This involves utilizing their proprietary CryoTC technology to provide essential frozen products to clinics worldwide.
Frequently Asked Questions
What is the ADS ratio change implemented by TC BioPharm?
The ADS ratio change adjusts the ratio from one ADS for 200 ordinary shares to one ADS for 4000 ordinary shares.
How does the ADS ratio change affect current ADS holders?
Current ADS holders must exchange twenty ADSs for one new ADS, maintaining their shareholder equity.
Will the ADS trading price change following the ratio adjustment?
It is expected that the ADS trading price will increase proportionally; however, no guarantees can be made regarding the price after the change.
What role does the Bank of New York Mellon play in this process?
The Bank of New York Mellon will manage the exchange of the ADSs and handle the sales of any fractional interests on behalf of the ADS holders.
What is the focus of TC BioPharm as a company?
TC BioPharm focuses on developing gamma-delta T cell therapies aimed primarily at treating cancer, with significant efficacy data in acute myeloid leukemia.
